Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative FOLFOXIRI plus surgery with lateral pelvic lymph node dissection for rectal cancer with suspected lateral node involvement
ChiCTR1900027940Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Oct 2017
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluorouracil, folinic acid, oxaliplatin and irinotecan in rectal cancer and rectal adenocarcinoma, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: 3-year disease-free survival rate. Started Oct 2017; status: recruiting.
02
Drugs
fluorouracilfolinic acidoxaliplatinirinotecan
03
Conditions
rectal cancerrectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR1900027940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027940.